lenvatinib has been researched along with Cardiovascular-Abnormalities* in 1 studies
1 other study(ies) available for lenvatinib and Cardiovascular-Abnormalities
| Article | Year |
|---|---|
Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report.
Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms. Topics: Aged; Cardiovascular Abnormalities; Combined Modality Therapy; Humans; Hypertension; Male; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Quinolines; Radiofrequency Ablation; Thyroid Cancer, Papillary | 2019 |